Dr. Joseph Cicenia from the Cleveland Clinic, comments on the recent REVOLENS publication

It's encouraging news for millions of people suffering from emphysema, a chronic lung disease which makes it difficult to breathe.

A recent French study shows people with emphysema report an increased quality of life after having special spring-like coils placed in their lungs.

REVOLENS Randomized Clinical Trial

January 12, 2016

Professors Gaetan Deslee and Charles-Hugo Marquette, Primary Investigators of the REVOLENS Study Group, “Lung Volume Reduction Coil Treatment vs. Usual Care in Patients with Severe Emphysema: The REVOLENS Randomized Clinical Trial” is published in the JAMA 2016;315(2):175-184.Doi:10.1001/jama.2015.17821.

“We congratulate the investigators and the French Ministry of Health for completing this randomized clinical trial and for publishing the study results in one of the world’s top-ranked medical journals.” said Matthew Gantz, Executive VP, BTG International Inc., and President, PneumRx, Inc. “We are pleased to see a growing evidence base supporting the use of endobronchial coils to improve the lives of patients with severe emphysema and look forward to this becoming a standard of care option in France.” 

To date, three (3) randomized, clinical trials of PneumRx’s coils have been completed: RESET (The Lancet Respiratory Medicine, 2013), REVOLENS (JAMA, 2016) and RENEW, the U.S. pivotal trial, which is expected to be published later in 2016.

Are you a Healthcare Professional?